{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T09:35:53Z","timestamp":1786440953611,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"crossref","award":["20nk0101601h0001"],"award-info":[{"award-number":["20nk0101601h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-60421-0","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T09:03:54Z","timestamp":1786439034000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["IRO-203: a novel intranasal COVID-19 vaccine showing immunogenicity and viral suppression in African green monkey challenge study"],"prefix":"10.1038","volume":"16","author":[{"given":"Kohji","family":"Kusano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinnosuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Washizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Takizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isamu","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6655-3678","authenticated-orcid":false,"given":"Jitsutaro","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyotaka","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"60421_CR1","unstructured":"World Health Organization. Coronavirus disease (COVID-19) pandemic (2025). https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019"},{"key":"60421_CR2","unstructured":"World Health Organization. Therapeutics and COVID-19 Guideline Development (2025). https:\/\/www.who.int\/teams\/health-care-readiness\/covid-19\/therapeutics"},{"key":"60421_CR3","doi-asserted-by":"publisher","first-page":"116","DOI":"10.20411\/pai.v6i1.441","volume":"6","author":"JK Thomas","year":"2021","unstructured":"Thomas, J. K. et al. Antibody responses to SARS-CoV-2 mRNA vaccines are detectable in saliva. Pathog Immun. 6, 116\u2013134 (2021).","journal-title":"Pathog Immun."},{"key":"60421_CR4","first-page":"1","volume":"12","author":"WYC Renee","year":"2021","unstructured":"Renee, W. Y. C. et al. The mucosal and serological immune responses to the novel coronavirus (SARS-CoV-2) vaccines. Front. Immunol. 12, 1\u20139 (2021).","journal-title":"Front. Immunol."},{"key":"60421_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/gtc.12992","volume":"28","author":"S Morimoto","year":"2023","unstructured":"Morimoto, S. et al. Intranasal Sendai virus-based SARS-CoV-2 vaccine using a mouse model. Genes Cells. 28, 29\u201341 (2023).","journal-title":"Genes Cells"},{"key":"60421_CR6","doi-asserted-by":"publisher","first-page":"921","DOI":"10.3390\/vaccines12080921","volume":"12","author":"DH Kim","year":"2024","unstructured":"Kim, D. H. et al. Intranasal administration of recombinant Newcastle disease virus expressing SARS-CoV-2 spike protein. Vaccines 12, 921 (2024).","journal-title":"Vaccines"},{"key":"60421_CR7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41541-023-00662-6","volume":"8","author":"C L\u00f3pez-Mac\u00edas","year":"2023","unstructured":"L\u00f3pez-Mac\u00edas, C. et al. Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico. NPJ Vaccines. 8, 67 (2023).","journal-title":"NPJ Vaccines"},{"key":"60421_CR8","doi-asserted-by":"publisher","first-page":"1524477","DOI":"10.3389\/fimmu.2025.1524477","volume":"16","author":"I Gonz\u00e1lez-Dom\u00ednguez","year":"2025","unstructured":"Gonz\u00e1lez-Dom\u00ednguez, I. et al. Mucosal multivalent NDV-based vaccine provides cross-reactive immune responses. Front. Immunol. 16, 1524477 (2025).","journal-title":"Front. Immunol."},{"key":"60421_CR9","unstructured":"Lamb, R. A. & Kolakofsky, D. Paramyxoviridae: The viruses and their replication. In Fields Virology 4th edn 1305\u20131340 (Lippincott-Raven, (2001)."},{"key":"60421_CR10","unstructured":"Karron, R. A. & Collins, P. L. Parainfluenza viruses. In Fields Virology 5th edn 1497\u20131526 (Lippincott Williams and Wilkins, (2007)."},{"key":"60421_CR11","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1016\/j.vaccine.2004.01.053","volume":"22","author":"SS Karen","year":"2004","unstructured":"Karen, S. S. et al. Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults. Vaccine 22, 3182\u20133186 (2004).","journal-title":"Vaccine"},{"key":"60421_CR12","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1128\/CVI.00618-14","volume":"22","author":"A Elisabeth","year":"2015","unstructured":"Elisabeth, A. et al. Safety and immunogenicity of an intranasal Sendai virus-based human parainfluenza virus type 1 vaccine in 3- to 6-year-old children. Clin. Vaccine Immunol. 22, 298\u2013303 (2015).","journal-title":"Clin. Vaccine Immunol."},{"key":"60421_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/infdis\/jiw500","volume":"215","author":"N Julien","year":"2017","unstructured":"Julien, N. et al. First-in-human evaluation of the safety and immunogenicity of an intranasally administered replication-competent Sendai virus\u2013vectored HIV type 1 Gag vaccine. J. Infect. Dis. 215, 95\u2013104 (2017).","journal-title":"J. Infect. Dis."},{"key":"60421_CR14","doi-asserted-by":"publisher","first-page":"6564","DOI":"10.1128\/JVI.74.14.6564-6569.2000","volume":"74","author":"H Li","year":"2000","unstructured":"Li, H. et al. A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression. J. Virol. 74, 6564\u20136569 (2000).","journal-title":"J. Virol."},{"key":"60421_CR15","doi-asserted-by":"publisher","first-page":"e02298","DOI":"10.1128\/JVI.02298-16","volume":"91","author":"MA Wiegand","year":"2017","unstructured":"Wiegand, M. A. et al. A respiratory syncytial virus vaccine vectored by a stable chimeric and replication\u2013deficient Sendai virus protects mice without inducing enhanced disease. J. Virol. 91, e02298\u2013e02216 (2017).","journal-title":"J. Virol."},{"key":"60421_CR16","doi-asserted-by":"publisher","first-page":"636","DOI":"10.2745\/dds.22.636","volume":"22","author":"M Inoue","year":"2007","unstructured":"Inoue, M. Development of vaccine technology using Sendai virus vector. Drug Delivery Syst. (DDS). 22, 636\u2013645 (2007).","journal-title":"Drug Delivery Syst. (DDS)"},{"key":"60421_CR17","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.vaccine.2011.11.046","volume":"30","author":"BG Jones","year":"2012","unstructured":"Jones, B. G. et al. Sendai virus\u2013based RSV vaccine protects African green monkeys from RSV infection. Vaccine 30, 959\u2013968 (2012).","journal-title":"Vaccine"},{"key":"60421_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/infdis\/jiw500","volume":"215","author":"J Nyombayire","year":"2017","unstructured":"Nyombayire, J. et al. First-in-human evaluation of the safety and immunogenicity of an intranasally administered replication-competent Sendai virus\u2013vectored HIV type 1 Gag vaccine. J. Infect. Dis. 215, 95\u2013104 (2017).","journal-title":"J. Infect. Dis."},{"key":"60421_CR19","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.3390\/microorganisms9081744","volume":"9","author":"R Kalkeri","year":"2021","unstructured":"Kalkeri, R. et al. SARS-CoV-2 spike pseudoviruses: a useful tool to study virus entry and address emerging neutralization escape phenotypes. Microorganisms 9, 1744 (2021).","journal-title":"Microorganisms"},{"key":"60421_CR20","doi-asserted-by":"publisher","first-page":"107764","DOI":"10.1016\/j.isci.2023.107764","volume":"26","author":"T Gilliland","year":"2023","unstructured":"Gilliland, T. et al. Transchromosomic bovine-derived anti-SARS-CoV-2 polyclonal human antibodies protect hACE2 transgenic hamsters against multiple variants. iScience 26, 107764 (2023).","journal-title":"iScience"},{"key":"60421_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1089\/aid.2008.0212","volume":"25","author":"CD Harro","year":"2009","unstructured":"Harro, C. D. et al. Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines. AIDS Res. Hum. Retroviruses. 25, 103\u2013114 (2009).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"60421_CR22","doi-asserted-by":"crossref","unstructured":"Lu, M. et al. A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike. Proc. Natl. Acad. Sci. USA 118 (2021).","DOI":"10.1073\/pnas.2026153118"},{"key":"60421_CR23","doi-asserted-by":"crossref","unstructured":"Zhang, Y. et al. A highly efficacious live attenuated mumps virus-based SARS-CoV-2 vaccine candidate. Proc. Natl. Acad. Sci. USA 119 (2022).","DOI":"10.1073\/pnas.2201616119"},{"key":"60421_CR24","doi-asserted-by":"publisher","first-page":"103810","DOI":"10.1016\/j.ebiom.2021.103810","volume":"75","author":"O Launay","year":"2022","unstructured":"Launay, O. et al. Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 \/ TMV-083. EBioMedicine 75, 103810 (2022).","journal-title":"EBioMedicine"},{"key":"60421_CR25","doi-asserted-by":"publisher","first-page":"103811","DOI":"10.1016\/j.ebiom.2021.103811","volume":"75","author":"F Vanhoutte","year":"2022","unstructured":"Vanhoutte, F. et al. Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591. EBioMedicine 75, 103811 (2022).","journal-title":"EBioMedicine"},{"key":"60421_CR26","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.3390\/v16121932","volume":"16","author":"M Bzami","year":"2024","unstructured":"Bzami, M. et al. Development and evaluation of a Newcastle disease virus-like particle vaccine expressing SARS-CoV-2 spike protein. Viruses 16, 1932 (2024).","journal-title":"Viruses"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60421-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60421-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60421-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T09:03:59Z","timestamp":1786439039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60421-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["60421"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-60421-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors are employees or executives of ID Pharma Co., Ltd., a pharmaceutical company that is developing the IRO-203 vaccine described in this study. The authors declare that there are no other financial or personal relationships that could have influenced the work reported in this paper.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"24723"}}